
CVS Health (CVS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
94.6B
Gross Profit
14.4B
15.22%
Operating Income
3.4B
3.57%
Net Income
1.8B
1.88%
EPS (Diluted)
$1.41
Balance Sheet Metrics
Total Assets
255.6B
Total Liabilities
178.5B
Shareholders Equity
77.1B
Debt to Equity
2.31
Cash Flow Metrics
Operating Cash Flow
4.0B
Free Cash Flow
3.8B
Revenue & Profitability Trend
CVS Health Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 372.8B | 357.8B | 322.5B | 292.1B | 268.7B |
Cost of Goods Sold | 321.4B | 303.3B | 268.0B | 240.0B | 219.7B |
Gross Profit | 51.4B | 54.4B | 54.5B | 52.1B | 49.0B |
Gross Margin % | 13.8% | 15.2% | 16.9% | 17.8% | 18.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | - | - | - |
Other Operating Expenses | 41.6B | 39.8B | 38.2B | 37.0B | 35.1B |
Total Operating Expenses | 41.6B | 39.8B | 38.2B | 37.0B | 35.1B |
Operating Income | 9.8B | 14.6B | 16.3B | 15.1B | 13.9B |
Operating Margin % | 2.6% | 4.1% | 5.1% | 5.2% | 5.2% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 3.0B | 2.7B | 2.3B | 2.5B | 2.9B |
Other Non-Operating Income | -689.0M | -768.0M | -8.2B | -2.1B | -1.2B |
Pre-tax Income | 6.1B | 11.2B | 5.8B | 10.5B | 9.8B |
Income Tax | 1.6B | 2.8B | 1.5B | 2.5B | 2.6B |
Effective Tax Rate % | 25.4% | 25.1% | 25.9% | 24.2% | 26.3% |
Net Income | 4.6B | 8.4B | 4.3B | 8.0B | 7.2B |
Net Margin % | 1.2% | 2.3% | 1.3% | 2.7% | 2.7% |
Key Metrics | |||||
EBITDA | 14.5B | 19.1B | 20.7B | 19.8B | 18.6B |
EPS (Basic) | $3.67 | $6.49 | $3.29 | $6.00 | $5.48 |
EPS (Diluted) | $3.66 | $6.47 | $3.26 | $5.95 | $5.46 |
Basic Shares Outstanding | 1259000000 | 1285000000 | 1312000000 | 1319000000 | 1309000000 |
Diluted Shares Outstanding | 1259000000 | 1285000000 | 1312000000 | 1319000000 | 1309000000 |
Income Statement Trend
CVS Health Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 8.6B | 8.2B | 12.9B | 9.4B | 7.9B |
Short-term Investments | 2.4B | 3.3B | 2.8B | 3.1B | 3.0B |
Accounts Receivable | 14.6B | 15.6B | 11.7B | 10.5B | 9.7B |
Inventory | 18.1B | 18.0B | 19.1B | 17.8B | 18.5B |
Other Current Assets | 3.1B | 3.2B | 2.6B | 5.3B | 5.3B |
Total Current Assets | 68.6B | 67.9B | 65.6B | 60.0B | 56.4B |
Non-Current Assets | |||||
Property, Plant & Equipment | 15.9B | 17.3B | 17.6B | 19.1B | 20.7B |
Goodwill | 209.9B | 211.8B | 181.1B | 187.3B | 190.2B |
Intangible Assets | 27.3B | 29.2B | 24.8B | 29.0B | 31.1B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 4.8B | 4.7B | 4.6B | 4.7B | 4.6B |
Total Non-Current Assets | 184.6B | 181.9B | 162.6B | 173.0B | 174.3B |
Total Assets | 253.2B | 249.7B | 228.3B | 233.0B | 230.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 15.9B | 14.9B | 14.8B | 12.5B | 11.1B |
Short-term Debt | 7.5B | 4.7B | 3.5B | 5.9B | 7.1B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 1.2B | 2.5B | 2.8B | 5.6B | 5.8B |
Total Current Liabilities | 84.6B | 79.2B | 69.4B | 67.8B | 62.0B |
Non-Current Liabilities | |||||
Long-term Debt | 75.4B | 74.7B | 67.3B | 70.1B | 78.0B |
Deferred Tax Liabilities | 3.8B | 4.3B | 4.0B | 6.3B | 6.8B |
Other Non-Current Liabilities | 10.3B | 11.7B | 12.6B | 8.3B | 9.4B |
Total Non-Current Liabilities | 92.9B | 93.9B | 87.1B | 89.8B | 99.0B |
Total Liabilities | 177.5B | 173.1B | 156.5B | 157.6B | 161.0B |
Equity | |||||
Common Stock | 49.7B | 49.0B | 48.2B | 47.4B | 46.5B |
Retained Earnings | 62.8B | 61.6B | 56.4B | 54.9B | 49.6B |
Treasury Stock | 36.8B | 33.8B | 31.9B | 28.2B | 28.2B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 75.7B | 76.6B | 71.8B | 75.4B | 69.7B |
Key Metrics | |||||
Total Debt | 82.9B | 79.4B | 70.7B | 76.0B | 85.0B |
Working Capital | -16.0B | -11.3B | -3.8B | -7.8B | -5.6B |
Balance Sheet Composition
CVS Health Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 4.6B | 8.4B | 4.3B | 8.0B | 7.2B |
Depreciation & Amortization | 4.6B | 4.4B | 4.2B | 4.5B | 4.4B |
Stock-Based Compensation | 540.0M | 588.0M | 447.0M | 484.0M | 400.0M |
Working Capital Changes | -2.6B | -379.0M | 5.8B | 3.8B | 6.1B |
Operating Cash Flow | 6.0B | 12.7B | 13.1B | 15.9B | 17.7B |
Investing Activities | |||||
Capital Expenditures | -2.8B | -3.0B | -2.7B | -2.5B | -2.3B |
Acquisitions | -95.0M | -16.6B | -1.4B | -146.0M | -26.0M |
Investment Purchases | -15.2B | -9.0B | -7.7B | -10.0B | -9.6B |
Investment Sales | 10.4B | 7.7B | 6.7B | 7.2B | 6.5B |
Investing Cash Flow | -7.6B | -20.9B | -5.0B | -5.3B | -5.5B |
Financing Activities | |||||
Share Repurchases | -3.0B | -2.0B | -3.5B | 0 | - |
Dividends Paid | -3.4B | -3.1B | -2.9B | -2.6B | -2.6B |
Debt Issuance | 7.9B | 10.9B | 0 | 987.0M | 10.0B |
Debt Repayment | -4.8B | -8.2B | -4.2B | -10.3B | -15.6B |
Financing Cash Flow | -1.5B | -2.6B | -11.1B | -11.9B | -8.0B |
Free Cash Flow | 6.3B | 10.4B | 13.4B | 15.7B | 13.4B |
Net Change in Cash | -3.1B | -10.8B | -3.0B | -1.2B | 4.2B |
Cash Flow Trend
CVS Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
18.25
Forward P/E
10.11
Price to Book
1.07
Price to Sales
0.22
PEG Ratio
10.11
Profitability Ratios
Profit Margin
1.18%
Operating Margin
2.80%
Return on Equity
5.88%
Return on Assets
2.29%
Financial Health
Current Ratio
0.80
Debt to Equity
106.67
Beta
0.59
Per Share Data
EPS (TTM)
$3.59
Book Value per Share
$61.07
Revenue per Share
$304.54
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
cvs | 83.1B | 18.25 | 1.07 | 5.88% | 1.18% | 106.67 |
UnitedHealth | 244.5B | 11.69 | 2.58 | 21.65% | 5.04% | 75.58 |
Cigna | 74.9B | 15.39 | 1.86 | 13.18% | 1.92% | 76.10 |
Elevance Health | 65.9B | 12.40 | 1.50 | 12.42% | 2.83% | 68.84 |
Humana | 33.9B | 21.59 | 1.86 | 9.03% | 1.28% | 70.63 |
Centene | 12.9B | 6.35 | 0.47 | 7.44% | 1.29% | 63.91 |
Financial data is updated regularly. All figures are in the company's reporting currency.